NuoSiLande Announces Subsidiary's Oxymetazoline Hydrochloride Eye Drops Receives Approval for Phase III Clinical Trial

Gelonghui November 11th |NorthlandAnnouncement: Beijing Hui'en Land Pharmaceutical Co., Ltd., a subsidiary of Northland, has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its Oxybuprocaine Hydrochloride Eye Drops. The product specification is 0.1% (0.3ml:0.3mg), and the applied indication is for the treatment of acquired ptosis in adults. The application is for Phase III clinical trials. The approval conclusion is to agree to proceed with the clinical trial. The company will strictly organize according to national clinical trial requirements, and after completion of the work, submit relevant materials and apply for production and market launch. Market launch can only occur after approval, and there will be no significant short-term impact on performance.